Research & Development: Page 70
-
PharmaVoice Team/PharmaVoice
Experts
John C. Andrews, Ph.D. Director of Regulatory Affairs, Americas, Chiltern, a global CRO. For more information, visit chiltern.com. Jerome Bailey. VP, Early Phase Business Center, Omnicare Clinical Research, a full-service CRO with diverse therapeutic expertise and comprehensive clinical service o...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Phase IV: Technology Solutions
According to John Hall, global medical affairs, epidemiology and outcomes research, at Quintiles, electronic health record providers are at the leading edge of new solutions, and are providing more effective ways to collect data while protecting physician relationships. The industry faces several...
By Robin Robinson • March 4, 2010 -
Explore the Trendline➔
Stock via Getty Images
TrendlineBig Pharma Business Strategies
Large pharmas are consistently tasked with the goal of growth. But in recent years, the upward trajectory has been littered with new hurdles.
By PharmaVoice staff -
PharmaVoice Team/PharmaVoice
Phase III: Market Preparation
How the brand begins to be positioned across the spectrum of medical communications — specifically how the science behind the brand and trial results begin to be discussed at global and local congresses, from interactive and traditional exhibit stands to symposia, from posters to special social e...
By Robin Robinson • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Phase III Trials: Patient Recruitment and Data Collection
Two of the biggest bottlenecks in the drug development process, particularly at the Phase III juncture, are patient recruitment and data management. Experts say technology, partnering, and strategic planning can improve Phase III clinical trial efficiency. Phase III: Recruitment Technologies Acc...
By Robin Robinson • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Phase II: Testing Efficacy, Planning for Marketing
Pharmaceutical companies and their partners are working to address productivity and create efficiency in Phase II development. New types of trial designs, such as adaptive trials, are being considered as solutions to these perennial issues. “There are innovative ways in which biopharmaceutical co...
By Denise Myshko • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Phase I: Patient Recruitment
According to Peter Smith, Ph.D., senior VP, nonclinical development sciences at Millennium Pharmaceuticals: The Takeda Oncology Company, shortages in funding, manpower, and patient availability have created the proverbial perfect storm in the current clinical trial system. “The fact that traditio...
By Denise Myshko • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Phase I: From Animals to First-in-Human Studies
The simple study designs of the past have been replaced with more complex designs with the addition of more screening and study procedures, biomarkers, and pharmacokinetic samples requirements, as well as longer study exposure periods. The trend today is conducting more rigorous, early-phase clin...
By Denise Myshko • March 4, 2010 -
PharmaVoice Team/PharmaVoice
CROs and Preclinical Development
To create efficiency and offload the need to maintain staff, instruments, and consumables for irregularly scheduled projects and projects that extend beyond their scope, more labs are engaging CROs as outsourcing partners, according to a recent report by BioInformatics LLC. Thomas Jones, Ph.D., s...
By Denise Myshko • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Preclinical Development: Linking the Lab to Human Trials
The challenge of pharmaceutical discovery and development as a whole is that a large number of conditions need to be met in order for a single molecular entity to successfully reach the market, says Thomas Jones, Ph.D., senior director, toxicology and pathology, Eli Lilly and Company. “The molecu...
By Denise Myshko • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Drug Discovery: From Compound to Product Candidate
The first step in finding a drug to bring to the clinic is screening chemical compound databases against a protein target. There are several phases that comprise early development, including target identification and validation, hit finding, and lead optimization. Activities during these steps, w...
By Denise Myshko • March 4, 2010 -
PharmaVoice Team/PharmaVoice
A Long and Winding Road
In today’s biopharma economy, declining R&D productivity combined with increased development costs have made investment portfolio managers skittish, says Chip Gillooly, VP, capital, at Quintiles. “The risks associated with investments are high, and the lack of output is making everyone nervou...
By Taren Grom • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Last Word
Pfizer’s Mark Swindell discusses the integration of Wyeth’s vaccine business after the acquisition by Pfizer. As President of Vaccines, Mr. Swindell is helping to create a seamless process for melding the former Wyeth specialty business with Pfizer. One of the stated goals for the combined Pfize...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL John DUCKER, APP Pharmaceuticals Dr. Julie GERBERDING, Merck Dr. Michael ROSENBLATT, Merck Sean NOLAN, Lundbeck Inc. Derica RICE, Lilly Biotechnology POOL Dr. Mark BAGARAZZI, Inovio Biomedical Hans BISHOP, Dendreon Suzanne CADDEN, ImmunoGen Dr. Thomas HOFSTAETTER, VaxInnate Dr...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
E-media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: Perceptive Informatics Introduces E-Clinical Suite Elsevier Launches Online Resource Center for ARRA Updates Thomson Pharma Database Integrates Trial Protocol, Outcome Info Take Supply Chain Releases Multi-Tenant ...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: GxP Consulting Adds Statistical Analysis Support Former Wyeth VP Launches Petkus Communications Consultants GlobalHealth Provides Corporate Training, Degree Programs Newly Formed Durata Therapeutics Acquires Pfizer’s Vicuro...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Process Inefficiencies Cause $11 Billion in Annual Pharma Revenue Leakage Sidebar: Key Findings of Revenue Leakage Study Drug Companies Still Under Pressure to Increase Pace of Development Sidebar: Key Near-Term Trends i...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
As PharmaVOICE enters its 10th year, the basic premise on which we founded the publication, and the company, remains as true today as it did on that February afternoon back in 2001: there is a fundamental need to understand the life-sciences industry from a holistic perspective that cuts across i...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Last Word
Rewarding Performance Procter & Gamble is a recognized leader in consumer goods marketing. What, if any, learnings from the consumer-goods side of the business did the Prilosec OTC brand team employ in developing this program? Cleveland: Procter & Gamble and the Prilosec OTC new sponsor...
By PharmaVoice Team • Jan. 26, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology POOL Dr. Paul LAMMERS Mirna Appoints Chief Executive Mirna Therapeutics has named Paul Lammers, M.D., president and CEO. As head of Mirna, Dr. Lammers is responsible for driving the company’s discoveries in the field of microRNA (miRNA) into the clinic. Dr. Lammers was previously pr...
By PharmaVoice Team • Jan. 26, 2010 -
PharmaVoice Team/PharmaVoice
E-media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: IntraLinks, Adobe Collaborate on Data-Capture Solutions for Clinical Trials Maestro eLearning Creates e-Learning Library Deloitte Recap Helps Biopharma Executives Make Portfolio Decisions Thomson Reuters Unveil...
By PharmaVoice Team • Jan. 26, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Companies Advised to Communicate with Payers Earlier in Drug Development Sidebar: Average Allocation of a Managed Markets Department’s Personnel Pharma Companies Add Employer Market to the Mix Sidebar: Employer Programs...
By PharmaVoice Team • Jan. 25, 2010 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
In our lifetime… There are few, if any, of us who can say we have been lucky enough to escape the ravaging effects of cancer — be it ourselves, a significant other, family member, or friend. For more years than I care to remember, “a cure for cancer" has been just around the corner. Recently, Pre...
By Taren Grom • Jan. 25, 2010 -
PharmaVoice Team/PharmaVoice
Dr. Alan E. Guttmacher — In the genes
AS THE RECENTLY APPOINTED SECOND DEPUTY DIRECTOR OF THE NATIONAL HUMAN GENOME RESEARCH INSTITUTE,THE INSTITUTION RESPONSIBLE FOR LEADING THE HUMAN GENOME PROJECT, DR.ALAN GUTTMACHER’S EXTENSIVE CLINICAL GENETICS BACKGROUND WILL BE INVALUABLE AT A TIME WHEN RESEARCHERS ARE BEGINNING TO TRANSLATE T...
By Kim Ribbink • Jan. 18, 2010 -
PharmaVoice Team/PharmaVoice
The Package Deal
PharmaVOICE Container or labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, or device, or any likeness thereof, of a drug manufacturer, pro cessor, packer, or distributor other than the per son or persons who in fact manufactured, pro ce...
By Elizabeth Pena • Jan. 18, 2010 -
PharmaVoice Team/PharmaVoice
E-Media
E-MEDIA NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES FDAnews has launched Drug Industry Daily, an electronic daily publication that provides news coverage of what’s happening on Capitol Hill, in the courts, and at the Food and Drug Administration, the Federal Trade Commission...
By PharmaVoice Team • Jan. 14, 2010
Previous
